alexa A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Desvenlafaxine Extended-Release Tablets in Generalized Social Anxiety Disorder | OMICS International | Abstract
ISSN: 2167-1044

Journal of Depression and Anxiety
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Desvenlafaxine Extended-Release Tablets in Generalized Social Anxiety Disorder

Michael R. Liebowitz*, Ester Salmán, Ann Johnso and Rita Hanover
The Medical Research Network, LLC, New York
*Corresponding Author : Michael R. Liebowitz
MD, 134 East 93rd Street
Suite 201A, New York, NY 10128, USA
Tel: (212) 595-5012
Fax: (212) 595-5013
E-mail: [email protected]
Received May 13, 2015; Accepted June 17, 2015; Published June 20, 2015
Citation: Liebowitz MR, Salmán E, Johnso A, Hanover R (2015) A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Desvenlafaxine Extended-Release Tablets in Generalized Social Anxiety Disorder. J Depress Anxiety S1:014. doi:10.4172/2167-1044.S1-014
Copyright: © 2015 Liebowitz MR, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Abstract Objective: The purpose of the study was to asses the efficacy of desvenlafaxine in patients with the generalized form of Social Anxiety Disorder (GSAD). Methods: 63 patients with GSAD were randomized to desvenlafaxine or placebo in a 12 week double blind trial. Change from baseline to endpoint on the Liebowitz Social Anxiety Scale (LSAS) was the primary outcome measure. Secondary outcome measures included response, defined as much improved or very much improved on the Clinical Global Impression of Change (CGI-I) and remission rates (defined as the proportion of patients with an endpoint LSAS total score of 30 or less. Changes in depression and anxiety, measured by the Hamilton Depression (Ham-D 17) and Anxiety Scales (Ham-A), were also assessed. Outcome analyses were performed in the intent to treat (ITT) and completer samples. Results: The mean baseline LSAS was 92.8 and mean Clinical Global Impression of Severity (CGI-S) was 5.4, indicating severe illness, with no baseline differences between treatment groups. At the end of treatment, in the ITT sample (N=58), the drug group had improved more than the placebo group by 9.7 points on the LSAS, a trend difference (p=0.085, 1 tailed). Cohen’s d was 0.36, indicative of a moderate effect size. There were also trend differences in response (69% versus 48.3%, p=0.09, 1 tailed) and remission rates (20.7% versus 3.4%, p=0.051, t tailed), and significant differences on the Hamilton Depression scale (2.5 versus 0.3, p=0.02, 1 tailed) in favor of desvenlafaxine. Findings in the completer sample were similar to those in the ITT sample. Conclusions: These findings must be considered preliminary because the limited sample size reduced statistical power and renders interpretation of the findings less precise.. Nevertheless these initial results suggest that desvenlafaxine has efficacy for social anxiety disorder similar to that seen with more extensively studied medications that have received FDA approval for this condition. Therefore, pending further study, desvenlafaxine may prove to be a useful treatment for Social Anxiety Disorder.

Keywords

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7